Lipoproteins and the progression/regression of atherosclerosis.
Lipoproteins and the impact of lipid lowering on progression and regression of coronary artery disease are discussed. Angiographically assessed regression studies are reviewed (NHLBI, LIT, LHT, CLAS I and II, FATS, POSCH, Heidelberg, STARS, SCRIP, MAAS, PLAC I, HARP, UC-SF), as are B-mode ultrasound studies (ACAPS, PLAC II) and survival studies (Oslo diet-smoking study, SSSS, Pravastatin, Oxford). Although study populations and the interventions are different in the studies, I have come to the following conclusions. Regression of atherosclerosis correlates well with reduction in LDL cholesterol and an increase in HDL cholesterol. Although overall improvement in the severity and extent of the disease was modest, reduction of clinical events was impressive. Lipid modulation may stabilize existing lesions by improving the stability of the lesion cap and/or promoting loss of cholesterol content from within the plaque. Survival studies indicate that lipid lowering lowers morbidity and increases longevity in patients with established coronary heart disease. The B-mode ultrasound studies using the carotid artery as surrogate for the change in atherosclerosis in the coronary seems extremely promising. The atherosclerotic process as well as complications may be studied at an early stage using noninvasive methods.
Barth
J D
JD
Department of Medicine (Cardiology), University of Southern California, Los Angeles 90033, USA.
D001161:Arteriosclerosis / Q000097:blood* / Q000503:physiopathology* / Q000628:therapy; D002986:Clinical Trials as Topic; D017023:Coronary Angiography; D003327:Coronary Disease / Q000209:etiology; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D008074:Lipoproteins / Q000097:blood*; D012074:Remission Induction
D008074:Lipoproteins